Cell and gene therapy company offering affordable CAR-T treatment for blood cancers.
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Series B Immuneel Therapeutics raised ₹100 Cr (~$10.5M) in a Series B from Singularity AMC and Rainmatter to take its CAR-T gene therapy to global markets. | $10.5M |
| Jun 2022 | Series A Biotech startup Immuneel Therapeutics raised ~$15M in a Series A led by Eight Roads Ventures, True North Fund and F-Prime Capital. | $15M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.